Directorate Change

RNS Number : 7921K

Oxford Biomedica PLC

05 January 2016

 

Board change

Oxford, UK - 5 January 2016: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, announces that Dan Soland has been required to step down as a Non-Executive Director, due to his appointment as CEO of uniQure with immediate effect.

Commenting on the announcement, Dan Soland, said: "It is with regret that I have to step down as a Board member of Oxford BioMedica as a result of my appointment as CEO of uniQure. Oxford BioMedica has an outstanding position as a world-leader in gene and cell-therapy.  The Company has an excellent business model well balanced by an exciting pipeline of wholly owned products, sought-after IP and third party manufacturing and process development.  With its strong management team, I have no doubt that Oxford BioMedica is en route to long-term success and I have greatly enjoyed working with the team.  I step down from my role feeling I leave the Company in an extremely strong position."

Oxford BioMedica's Chairman*, Nick Rodgers, said: "Dan has made a valuable contribution to Oxford BioMedica. We thank him for his input and wish him well for the future."

*Oxford BioMedica announced on 15 December 2015 that Lorenzo Tallarigo (experience includes: Intercept Pharmaceuticals, Genextra and Eli Lilly) has been appointed as Non-Executive Chairman of the Group and will join on 1 February 2016.

-Ends-

For further information, please contact:
Oxford BioMedica plc: John Dawson, Chief Executive Officer Tim Watts, Chief Financial Officer	Tel: [phone]
Financial and corporate communications enquiries: Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton	Tel: [phone]

Notes for editors

About Oxford BioMedica^®

Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy group with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world's largest pharmaceutical companies. Leveraging its proprietary LentiVector^® IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of seven gene therapy products addressing diseases for which there are currently no treatments or that are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Group's industry-leading manufacturing and development business, provides services to collaborators and partners working in gene and cell therapy, including Novartis and Immune Design Corp.  In addition, the Group has licenced products and IP to Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk.

 

END

 

 

BOAUGUAPGUPQGRC